Reading for pleasure during childhood may lead to higher brain/ cognitive development and mental well-being during adolescence

By The Conversation | July 19, 2023 |

Ear­ly child­hood is a crit­i­cal peri­od for brain devel­op­ment, which is impor­tant for boost­ing cog­ni­tion and men­tal well­be­ing. Good brain health at this age is direct­ly linked to bet­ter men­tal heath, cog­ni­tion and edu­ca­tion­al attain­ment in ado­les­cence and adult­hood. It can also pro­vide resilience in times of stress. But, sad­ly, brain devel­op­ment can be hampered…

Read More

Virtual cognitive behavioural therapy (CBT) accounts for over 30% of NHS mental health treatments — up from 10% in 2017

By SharpBrains | July 12, 2023

Con­cern as a third of NHS men­tal health treat­ments shift online (The Guardian): An Observ­er analy­sis of data from pri­vate providers, cross-checked against NHS fig­ures, reveals around one in three men­tal health treat­ments in Eng­land are deliv­ered online, up from one in five in 2019, and one in 10 in 2017. Patients with mild to…

Read More

Major evidence review supports an “exercise prescription” for most adults to boost mental health and well-being

By Greater Good Science Center | July 6, 2023

When you head to your week­ly yoga class or lift weights at the gym, you’re doing some­thing good for your phys­i­cal health: get­ting more fit today, and so pro­tect­ing your body into the future. What you may not always think about, though, is that you’re also pro­tect­ing your­self from anx­i­ety and depression—about as much as…

Read More

Should doctors prescribe Leqembi (lecanemab) to women with early Alzheimer’s Disease? The evidence-based answer is probably No

By SharpBrains | June 28, 2023

Wel­come to a new edi­tion of Sharp­Brains e‑newsletter, fea­tur­ing this time a range of inter­ven­tions for brain/ cognitive/ men­tal health plus a few brain teasers to test our per­cep­tion and cog­ni­tive skills. #1. Should doc­tors pre­scribe lecanemab (Leqem­bi) to women? The answer, giv­en avail­able evi­dence, is prob­a­bly No Huge (and most­ly over­looked) red flag regard­ing newly…

Read More

Growing controversy over role of FDA and Medicare in promoting anti-amyloid drugs given limited benefit, high cost, severe side-effects

By SharpBrains | June 21, 2023

The War Over Whether Medicare Should Pay For The New Anti-Alzheimer’s Drugs (Forbes): The pow­er­ful Alzheimer’s Dis­ease lob­by is fight­ing a mul­ti-bil­lion-dol­lar bat­tle on two fronts. It is qui­et­ly try­ing to lim­it restric­tions the Food and Drug Admin­is­tra­tion puts on the use of new drugs aimed at slow­ing the pro­gres­sion of the brain dis­ease. And…

Read More